HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.

Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M Comoglio, Alberto Bardelli, Livio Trusolino, None, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. ,vol. 1, pp. 508- 523 ,(2011) , 10.1158/2159-8290.CD-11-0109

V Martin, L Landi, F Molinari, G Fountzilas, R Geva, A Riva, P Saletti, S De Dosso, A Spitale, S Tejpar, K T Kalogeras, L Mazzucchelli, M Frattini, F Cappuzzo, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients British Journal of Cancer. ,vol. 108, pp. 668- 675 ,(2013) , 10.1038/BJC.2013.4

Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial Lancet Oncology. ,vol. 17, pp. 738- 746 ,(2016) , 10.1016/S1470-2045(16)00150-9

Kanwal Pratap Singh Raghav, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Bryan K. Kee, Andrea Muranyi, Shalini Singh, Mark Routbort, Ken Chen, Kenna Rael Shaw, Kandavel Shanmugam, Dipen M. Maru, Marwan Fakih, Scott Kopetz, HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. Journal of Clinical Oncology. ,vol. 34, pp. 3517- 3517 ,(2016) , 10.1200/JCO.2016.34.15_SUPPL.3517

Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, Alessia Mennitto, Rosa Berenato, Federica Perrone, Annunziata Gloghini, Elena Tamborini, Sara Lonardi, Federica Morano, Benedetta Picciani, Adele Busico, Chiara Costanza Volpi, Antonia Martinetti, Francesca Battaglin, Ilaria Bossi, Alessio Pellegrinelli, Massimo Milione, Chiara Cremolini, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud, Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer Clinical Cancer Research. ,vol. 23, pp. 2414- 2422 ,(2017) , 10.1158/1078-0432.CCR-16-1863

Cornelis J. A. Punt, Miriam Koopman, Louis Vermeulen, From tumour heterogeneity to advances in precision treatment of colorectal cancer Nature Reviews Clinical Oncology. ,vol. 14, pp. 235- 246 ,(2017) , 10.1038/NRCLINONC.2016.171

John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock, Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study Journal of Clinical Oncology. ,vol. 36, pp. 536- 542 ,(2018) , 10.1200/JCO.2017.75.3780

Alberto Bardelli, Giulia Siravegna, Andrea Sartore-Bianchi, Rebecca J Nagy, Benedetta Mussolin, Andrea Cassingena, Cosimo Martino, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Alessio Amatu, Livio Trusolino, Justin Odegaard, Richard B. Lanman, Silvia Marsoni, Salvatore Siena, Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer. Journal of Clinical Oncology. ,vol. 36, pp. 3506- 3506 ,(2018) , 10.1200/JCO.2018.36.15_SUPPL.3506

Christine Megerdichian Parseghian, Jonathan M. Loree, Van Karlyle Morris, Allan Andresson Lima Pereira, Eduardo Vilar Sanchez, Bryan K. Kee, Kanwal Pratap Singh Raghav, A. Dasari, Ji Wu, Victoria M. Raymond, Kimberly Banks, AmirAli Talasaz, Richard B. Lanman, Michael J. Overman, Scott Kopetz, Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. Journal of Clinical Oncology. ,vol. 36, pp. 3511- 3511 ,(2018) , 10.1200/JCO.2018.36.15_SUPPL.3511